Biosimilars

Biologics currently represent the majority of health care spending both for employers and patients in need of these treatments. This highlights the importance of focusing on the opportunity available in —–. To reduce cost and increase access to life-saving treatments for patients, PBGH works with employers and purchasers to assess and break through barriers to adopting biosimilars.

Resources

Biosimilar Adoption: Challenges and Opportunities

Two Employer Plan Sponsors Biosimilar Savings Analysis

The purpose of this study was to assess potential savings from using biosimilars instead of reference biologic drugs, based on market pricing, potential rebates foregone, and biosimilar uptake.

decorative image

Biosimilars from the Physician Perspective

Biosimilars offer hope for competition in the high-cost specialty drug space where costs continue to skyrocket.

decorative image

ACOs and Biosimilars

Misaligned financial incentives and opaque drug purchasing arrangments appear to be the primary culprits preventing the robust adoption of biosimilars in the U.S. market.

Past Events and Training

August 12, 2020

Biosimilars: The Next Frontier

The widespread use of biosimilars brings competition to the drug market and is estimated to save more than $54 billion over ten years.